Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial

CONTEXT: Methodological shortcomings often compromise investigations into the effects of primary somatostatin-analog treatment on tumor size in acromegaly. There are also limited data for the long-acting lanreotide formulation. OBJECTIVE: The aim of the study was to better characterize the effects o...

Descripción completa

Detalles Bibliográficos
Autores principales: Caron, Philippe J., Bevan, John S., Petersenn, Stephan, Flanagan, Daniel, Tabarin, Antoine, Prévost, Gaëtan, Maisonobe, Pascal, Clermont, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2014
Materias:
Endocrine Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009579/
https://www.ncbi.nlm.nih.gov/pubmed/24423301
http://dx.doi.org/10.1210/jc.2013-3318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009579/
https://www.ncbi.nlm.nih.gov/pubmed/24423301
http://dx.doi.org/10.1210/jc.2013-3318

Ejemplares similares